UY25765A1 - Formulaciones farmacéuticas de liberación controlada - Google Patents

Formulaciones farmacéuticas de liberación controlada

Info

Publication number
UY25765A1
UY25765A1 UY25765A UY25765A UY25765A1 UY 25765 A1 UY25765 A1 UY 25765A1 UY 25765 A UY25765 A UY 25765A UY 25765 A UY25765 A UY 25765A UY 25765 A1 UY25765 A1 UY 25765A1
Authority
UY
Uruguay
Prior art keywords
inhibitor
cgmp pde
core
formulations
formulation
Prior art date
Application number
UY25765A
Other languages
English (en)
Inventor
Ross James Macrae
Elizabeth King
Original Assignee
Pfizer Res And Dev Company Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25765(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9823192.1A external-priority patent/GB9823192D0/en
Priority claimed from GBGB9825117.6A external-priority patent/GB9825117D0/en
Priority claimed from GBGB9826392.4A external-priority patent/GB9826392D0/en
Application filed by Pfizer Res And Dev Company Nv filed Critical Pfizer Res And Dev Company Nv
Publication of UY25765A1 publication Critical patent/UY25765A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención proporciona formulaciones farmacéuticas de liberación controlada para administración oral que contienen un inhibidor GMPc PDE-5; con la condición de que la formulación no conste esencialmente de sildenafil, óxido de polietileno de bajo peso molecular, hidroxipropil hipromelosa, excipentes para formar comprimidos y, opcionalmente, uno o más polímeros entéricos. Preferiblemente, las formulaciones de acuerdo con la presente invención son formulaciones de liberación sostenida, por ejemplo, se prefiere que hasta un 75% en peso del ingrediente activo se libere de la formulación en el tracto gastrointestinal (o en un modelo del tracto GI) después de un período de tiempo en el intervalo de 1 a 24 horas desde la administración. Preferiblemente, el inhibidor de la GMPc PDE-5 es sildenafil o una sal farmacéuticamente aceptable del mismo (tal como la sal de citrato): (5-(2-etoxi-5-(4-metil-1-piperazinilsulfonil)fenil)-1,6-dihidro-1-metil-3-propilpirazolo(4,3-d)pirimidin-7-ona). Ver fórmula (I). El inhibidor de GMPc PDE-5 está incrustado en una matriz de la cual se libera por difución o erosión, estando presente en un núcleo que se recubre con una membrana controladora de la velocidad de liberación. Dicha membrana comprende un copolímero de metacrilato de amonio y un plastificante. Un procedimiento para la preparación de una formulación según se define, incluye las etapas de: a) mezclar el inhibidor de GMPc PDE-5 con un material de matriz y prensar para formar el comprimido; b) formar un núcleo que comprende el inhibidor GMPc PDE-5 y después recubrir el núcleo con una membrana controladora de la velocidad de liberación; o c) formar un núcleo que contiene el inhibidor de GMPc PDE-5 y después recubrir el núcleo con un recubrimiento impermeable al inhibidor de GMPc PDE-5; respectivamente. Las formulaciones son útiles, entre otros, en el tratamiento o prevención de la disfunción sexual.
UY25765A 1998-10-23 1999-10-22 Formulaciones farmacéuticas de liberación controlada UY25765A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9823192.1A GB9823192D0 (en) 1998-10-23 1998-10-23 Pharmaceutical formulations
GBGB9825117.6A GB9825117D0 (en) 1998-11-16 1998-11-16 Pharmaceutical formulations
GBGB9826392.4A GB9826392D0 (en) 1998-11-27 1998-11-27 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
UY25765A1 true UY25765A1 (es) 2001-08-27

Family

ID=27269526

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25765A UY25765A1 (es) 1998-10-23 1999-10-22 Formulaciones farmacéuticas de liberación controlada

Country Status (44)

Country Link
US (1) US6964780B1 (es)
EP (1) EP1123088B1 (es)
JP (1) JP2002528408A (es)
KR (1) KR20010075659A (es)
CN (1) CN1324233A (es)
AP (1) AP2001002125A0 (es)
AT (1) ATE340562T1 (es)
AU (1) AU756509B2 (es)
BG (1) BG65323B1 (es)
BR (1) BR9914718A (es)
CA (1) CA2348086C (es)
CO (1) CO5160262A1 (es)
CR (1) CR6326A (es)
CY (1) CY1106239T1 (es)
CZ (1) CZ20011427A3 (es)
DE (1) DE69933383T2 (es)
DK (1) DK1123088T3 (es)
DZ (1) DZ2923A1 (es)
EA (1) EA004068B1 (es)
EE (1) EE200100235A (es)
ES (1) ES2272082T3 (es)
GT (1) GT199900184A (es)
HK (1) HK1041818A1 (es)
HR (1) HRP20010285A2 (es)
HU (1) HUP0104318A3 (es)
ID (1) ID28232A (es)
IL (1) IL141764A (es)
IS (1) IS5865A (es)
MA (1) MA26700A1 (es)
MX (1) MXPA01004011A (es)
MY (1) MY130727A (es)
NO (1) NO20011933L (es)
NZ (1) NZ510275A (es)
OA (1) OA11664A (es)
PA (1) PA8484301A1 (es)
PE (1) PE20001286A1 (es)
PL (1) PL195789B1 (es)
PT (1) PT1123088E (es)
SK (1) SK286473B6 (es)
TR (1) TR200101103T2 (es)
TW (1) TW577756B (es)
UA (1) UA67802C2 (es)
UY (1) UY25765A1 (es)
WO (1) WO2000024383A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230154B1 (hu) * 1997-11-12 2015-09-28 Bayer Intellectual Property Gmbh Eljárás 2-es helyzetben fenil-szubszituenst hordozó imidazo-triazinon-származékok előállítására
SK287674B6 (sk) 1998-11-02 2011-05-06 Elan Pharma International Limited Mnohočasticový prostriedok s modifikovaným uvoľňovaním obsahujúci metylfenidát, pevná orálne dávková forma s jeho obsahom a jeho použitie
EP1623703B1 (en) 1999-10-29 2011-10-05 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CN1264574C (zh) 2000-09-06 2006-07-19 田边制药株式会社 口服制剂
KR100968128B1 (ko) 2000-10-30 2010-07-06 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
CA2437754C (en) * 2001-02-15 2010-05-18 Tanabe Seiyaku Co., Ltd. Tablets quickly disintegrated in oral cavity
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ITMI20020515A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
MX347237B (es) 2004-05-11 2017-04-20 Eb Ip Lybrido B V Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
GB0421121D0 (en) * 2004-09-22 2004-10-27 Natrocell Technologies Ltd Composite rodenticide
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
CA2613617A1 (en) * 2005-06-27 2007-01-04 Daniel Drai Compositions and methods for enhancement of sexual function
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
BRPI0616633A2 (pt) * 2005-09-29 2011-06-28 Bayer Healthcare Ag inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
ATE456369T1 (de) 2006-06-30 2010-02-15 Boehringer Ingelheim Int Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
KR20090045945A (ko) 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
JP2010532319A (ja) * 2007-06-13 2010-10-07 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 聴覚障害の処置用のｐｄｅ阻害剤
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
WO2009098697A1 (en) * 2008-02-08 2009-08-13 Dexxon Ltd. Modafinil and sildenafil dosage forms
US20110244050A1 (en) 2008-12-12 2011-10-06 Siegfried Rhein S.A. De C.V. Pulsed-release sildenafil composition and method for preparing said composition
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EA015250B9 (ru) * 2010-11-19 2013-10-30 Тева Фармасьютикал Индастриз, Лтд. Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления
JP6121990B2 (ja) 2011-05-13 2017-04-26 イービー アイピー ハイブリタブス ビー．ブイ． 薬物送達システム
WO2013016144A1 (en) * 2011-07-22 2013-01-31 Pom Wonderful, Llc Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN113995727B (zh) * 2021-11-08 2023-04-07 山东鲁抗医药股份有限公司 一种5型磷酸二酯酶抑制剂片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
JPS5748908A (en) * 1980-09-08 1982-03-20 Kyorin Pharmaceut Co Ltd Prolonged release type nicomol pharmaceutical
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1229856B (it) * 1989-04-20 1991-09-13 Recordati Chem Pharm Compresse a rilascio controllato contenenti flavossato.
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
EP0621032B1 (en) * 1993-04-23 2000-08-09 Novartis AG Controlled release drug delivery device
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
WO1997048382A2 (en) * 1996-06-18 1997-12-24 Otsuka Pharmaceutical Co., Ltd. Multiple-unit type prolonged action drug preparation
DK0941075T3 (da) * 1997-01-06 2003-07-14 Pfizer Smagsmaskerende farmaceutisk doseringsform med hurtig frigivelse
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
DK1109814T3 (da) * 1998-09-04 2004-08-02 Ortho Mcneil Pharm Inc 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion

Also Published As

Publication number Publication date
MY130727A (en) 2007-07-31
NO20011933L (no) 2001-06-25
KR20010075659A (ko) 2001-08-09
CZ20011427A3 (cs) 2001-10-17
EE200100235A (et) 2002-08-15
HRP20010285A2 (en) 2002-06-30
UA67802C2 (uk) 2004-07-15
TR200101103T2 (tr) 2001-09-21
IL141764A (en) 2008-06-05
HK1041818A1 (zh) 2002-07-26
PL347476A1 (en) 2002-04-08
DK1123088T3 (da) 2007-01-02
ID28232A (id) 2001-05-10
EA200100298A1 (ru) 2001-08-27
TW577756B (en) 2004-03-01
GT199900184A (es) 2001-04-14
BG105465A (bg) 2001-12-29
CR6326A (es) 2004-02-23
DZ2923A1 (fr) 2004-03-01
EP1123088A1 (en) 2001-08-16
PA8484301A1 (es) 2000-09-29
NZ510275A (en) 2003-07-25
MXPA01004011A (es) 2003-03-10
AU5878799A (en) 2000-05-15
MA26700A1 (fr) 2004-12-20
SK286473B6 (sk) 2008-11-06
CY1106239T1 (el) 2011-06-08
HUP0104318A3 (en) 2003-12-29
ES2272082T3 (es) 2007-04-16
CA2348086C (en) 2007-01-23
CO5160262A1 (es) 2002-05-30
PE20001286A1 (es) 2000-11-22
JP2002528408A (ja) 2002-09-03
CN1324233A (zh) 2001-11-28
US6964780B1 (en) 2005-11-15
WO2000024383A1 (en) 2000-05-04
DE69933383D1 (de) 2006-11-09
IL141764A0 (en) 2002-03-10
CA2348086A1 (en) 2000-05-04
SK5192001A3 (en) 2002-09-10
BR9914718A (pt) 2001-07-10
HUP0104318A2 (hu) 2002-03-28
IS5865A (is) 2001-02-27
BG65323B1 (bg) 2008-02-29
AP2001002125A0 (en) 2001-04-04
EA004068B1 (ru) 2003-12-25
EP1123088B1 (en) 2006-09-27
NO20011933D0 (no) 2001-04-19
DE69933383T2 (de) 2007-02-01
PT1123088E (pt) 2007-01-31
PL195789B1 (pl) 2007-10-31
AU756509B2 (en) 2003-01-16
ATE340562T1 (de) 2006-10-15
OA11664A (en) 2005-01-07

Similar Documents

Publication Publication Date Title
UY25765A1 (es) Formulaciones farmacéuticas de liberación controlada
ES2593582T3 (es) Formulación de comprimido recubierto y método
ES2585731T3 (es) Forma de dosificación farmacéutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina II y/o un diurético
ES2769357T3 (es) Formas farmacéuticas de apixaban
CA2566278A1 (en) Formulations with controlled release of active ingredient
ES2292819T3 (es) Composiciones farmaceuticas que comprenden acido micofenolico o sal de micofenolato.
RU2007111755A (ru) Фармацевтические полидисперсные композиции, включающие микофенольную кислоту или микофенолят натрия, и комбинации композиций с рапамицином
HUP0202495A2 (hu) Orális alkalmazásra szolgáló stabil gyógyszerkészítmény
CZ20002314A3 (cs) Orální farmaceutická dávková forma s prodlouženým uvolňováním
JP2004534057A5 (es)
ES2541124T3 (es) Nueva formulación farmacéutica que contiene una biguanida y un derivado de tiazolidinodiona
CZ3398A3 (cs) Použití inhibitorů cGMP fosfodiesterasy pro výrobu léčiva pro léčení impotence
WO2004108162A3 (en) Controlled release pharmaceutical composition
DE60133319D1 (de) Mehrfach beschichete pharmazeutische dosierungsform
RU2008103551A (ru) Фармацевтические препаративные формы, содержащие комбинацию действующих веществ из нифедипина и/или низолдипина и антагониста ангиотензина-ii
MX2008002512A (es) Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada.
ES2561085T3 (es) Preparación de liberación lenta de aceclofenaco que proporciona un efecto clínico farmacológico óptimo cuando se administra una vez al día
SI2729130T1 (en) Combined formulations of darunavir
Baum et al. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate
ITMI952221A1 (it) Composizioni farmaceutiche solide per uso vaginale
ES2340701T3 (es) Composicion farmaceutica solida que comprende irbesartan.
ES2689919T3 (es) Formulación farmacéutica multicapa
JPWO2003043661A1 (ja) 酸に不安定な生理活性化合物を含有する製剤組成物及びその製法
RS53443B (en) DOSAGE FORM CONTAINED BY PANTOPRAZOL AS ACTIVE INGREDIENT
KR102051132B1 (ko) 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20110623